Figure_4.tif (1.38 MB)

Induction of LXR markers by T0901317 on CD14+ and CD14− cells among PBMCs.

figure

posted on 2012-11-21, 02:17 authored by Cédric Rébé, Rodolphe Filomenko, Magalie Raveneau, Angélique Chevriaux, Minako Ishibashi, Laurent Lagrost, Jean Louis Junien, Philippe Gambert, David Masson

Isolated PBMCs were treated with DMSO or 10 µM T0901317 for 24 or 48 hours and CD226, CD244 or CD82 cell surface expression was evaluated by flow cytometry. A: Dot plot representing CD14− and CD14+ selected populations. B: CD226, CD244 or CD82 on CD14− cells. Right panel, representative histograms. Ig: control immunoglobulin; Ab: specific antibody. Left panel, MFI in LXR agonist- and DMSO- treated cells. Each bar is the mean ± S.E.M. of 4 independent experiments using cells from 4 distinct healthy donors. C: CD226, CD244 or CD82 on CD14+ cells. Right panel, representative histograms. Ig: control immunoglobulin; Ab: specific antibody. Left panel, MFI in LXR agonist- and DMSO- treated cells. Each bar is the mean ± S.E.M. of 4 independent experiments. Values are set at 1 in the DMSO conditions. * : significantly different from DMSO treatment (P<0.05 Wilcoxon T test). D: MFI in LXR agonist- and DMSO- treated PBMCswith or without 22-S-OH cholesterol added. Each bar is the mean ± S.E.M. of 3 independent experiments using CD14+ gated PBMCs from 3 distinct healthy donors. Values are set at 1 in the DMSO conditions. *: significantly different from DMSO treatment (P<0.05 Wilcoxon T test); †: significantly different from vehicle only conditions (P<0.05 Wilcoxon T test).